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SUMMARY 
Background: Foetal haemoglobin has been implicated 
in the modulation of sickle cell crisis. Its level is gener-
ally inversely proportional to the severity of sickle cell 
disease (SCD) for a given sickle cell phenotypes. The 
main aim of therapy for vaso-occlusive crisis (VOC), 
which is the hallmark of SCD, is to reduce the chances 
of sickling through the prevention of polymerization of 
HbS. One way of preventing this polymerization is by 
increasing foetal haemoglobin levels. 
Objectives: To determine the relationship between 
HbF levels and the frequency of crisis in SCD patients 
in Ghana.  
Method: A longitudinal retrospective survey covering 
a period of 30 months was carried out on adult SCD 
patients at the Sickle Cell Clinic of the Korle-Bu 
Teaching Hospital.  
Results: Eighty-three adults aged 15 to 65 years made 
up of 40 males and 43 femalea were studied. Analysis 
of variance (ANOVA) gave significant results in Hb 
and HbF levels. Higher HbF levels were positively 
related to less frequent crisis and were significantly 
high in SCD patients than in controls. HbF effects on 
the clinical manifestations on SCD were variable. 
Conclusion: Threshold values of HbF play a role in 
reducing the frequency of vaso-occlusive crisis in SCD 
patients and this finding contributes to the body of 
available literature on SCD severity. However our 
work does not give the apparent threshold level of 
helpful HBF Level in SCD.   
 




Sickle cell disease (SCD) is a major genetic disorder in 
tropical Africa.1In Ghana the prevalence rate is 1.9% of 
all births per year2 and is responsible for significantly 
high rate of morbidity and mortality in Ghana. SCD 
placed 37th and 36th positions in the years 2002 and 
2003 respectively on the out-patient morbidity reports 
compiled by the Ghana Health Service. Even though 
clinical manifestation of SCD displays a wide array of 
symptoms, recurrent attacks of VOC are responsible 
for most of the morbidity and mortality in SCD.2, 3 
 
Pathophysiologically, oxygenated Haemoglobin A 
(HbA) and Haemoglobin S (HbS) has the same solubil-
ity, but on deoxygenation, HbS is about 100 times less 
soluble.3The deoxygenated Haemoglobin S polymeriz-
es by sticking to each other to form long strands, which 
stretches the membrane of the red blood cell.4,5, 6 This 
defect causes polymerization of haemoglobin mole-
cules and erythrocyte sickling under hypoxic condi-
tions7, 8, 2 leading to VOC.  VOC is caused by sickled 
red blood cells which obstruct capillaries and restrict 
blood flow to an organ, resulting in ischemia, pain, and 
organ damage9, 10 and it is responsible for the high rate 
of morbidity3 and mortality2 in SCD. 
 
The disease severity depends primarily on the genotype 
which is ranked as HbSS > HbS/β°-thalassemia > 
HbSC > HbS/β+-thalassemia.11 The severity of the dis-
ease is also related to β-globin haplotypes, possibly due 
to variations in hemoglobin level and fetal hemoglobin 
concentrations. Nevertheless, haplotypes of the β-
globin gene cluster and α-globin complement affecting 
the expression of factors such as HbF, modulate the 
disease severity.12 Five haplotypes of the HbS allele 
have been identified from various populations based on 
two polymorphic clusters.12  
 
These clusters are thought to correlate with hematolog-
ical markers and HbF gene expression leading to a de-
creasing disease severity as Bantu > Cameroon > Benin 








However, work done by Inati et al., and a recent work14 
indicated that there are still atypical haplotypes that do 
not conform to literature.15 For instance, in one report 
from Lebanon, high HbF concentration was associated 
with increased disease severity16, a finding which war-
rants further investigation.   
 
Some genetic and environmental factors have been 
identified that ameliorate the severity of the SCD con-
dition. The most important of these is a high level of 
hemoglobin F (HbF) in the erythrocytes.17 The first 
insight into the role of foetal hemoglobin in the clinical 
manifestations of SCD was made by a pediatrician, 
Janet Watson.18 Watson and her colleagues at a New 
York hospital noted that babies with SCD rarely had 
manifestations of the condition in their first year of 
life.18 They proposed that the high level of HbF in the 
red cells, which persists during the first year of life, 
somehow protected the infant. Foetal Hb levels decline 
to their low levels of less than 2% six months after 
birth.19 The childhood manifestations of SCD are seen 
thereafter.  
 
Clinical observations have also confirmed that in-
creased foetal haemoglobin concentrations have bene-
ficial effects in SCD.20, 21, 22 Patients with SCD who 
have elevated HbF levels have fewer painful crises and 
improved survival20as shown by studies that fetal hae-
moglobin, which lacks β -globin chains, inhibits sick-
ling in vitro by interfering with the polymerization of 
haemoglobin S23, 24. Since polymerization of deoxy-
HbS is the signal event in the pathogenesis of SCD4, 
HbF could effectively prevent disease manifestation. 
 
Patients with sickle cell disease who also have heredi-
tary persistence of foetal haemoglobin (HPFH) often 
have few if any symptoms19. In these individuals, HbF 
usually comprises greater than 20% of the haemoglobin 
in the erythrocytes. It has been documented that in-
creased HbF levels ameliorate the severity and fre-
quency of painful crisis in SCD patients.20, 21, 22 Studies 
within populations of African origin have also shown 
that high HbF levels are associated with milder dis-
ease.26, 27, 28 
 
However, the role of HbF on the clinical sub phenotype 
is variable and inconsistent such that even levels near-
ing20% may be found in patients with severe disease. 
The threshold for significant reduction in acute epi-
sodes of pain, chest syndromes, and priapism is 20%, 
and for organ damage, 10%.  
 
A retrospective study in Jamaica did not find signifi-
cant difference in painful episodes or acute chest syn-
drome between different levels of HbF level,29 whilst 
no protective effect of HbF was found in studies by 
Baum.30However, a clear protective effect was found in 
the Co-operative Study in the USA17, 21, 31also found no 
linear relationship between HbF and clinical severity, 
but proposed that there were `threshold levels' above 
which HbF was an ameliorating factor (10% for stroke, 
20% for recurrent events such as painful crises).  
 
Several cytotoxic agents such as hydroxyurea25, 32 and 
5-azacytidine33,34 enhance the levels of foetal hemoglo-
bin developing erythroid cells. Hydroxyurea has been 
administered to patients with sickle cell disease in an 
effort to enhance foetal hemoglobin production.35 
Hydroxyurea induces foetal haemoglobin production35-
38 increases the red cell mean corpuscular volume, and 
reduces the number of dense cells and irreversibly sick-
led cells in the circulation,24 thereby reducing morbidi-
ty and mortality in SCD patients.38Treatment with hy-
droxyurea caused a 44%reduction in the median annual 
rate of painful crises in patients with SCD.23 
 
The possible benefit of HbF in reducing the frequency 
of crisis in SCD in Ghana is  not clear. This study will 
give a better understanding of the relationship between 
HbF levels and the frequency of crisis in SCD. 
 
MATERIALS AND METHODS 
The study was limited to patients with the HbSS and 
HbSC phenotypes. Voluntary blood donors at the Na-
tional blood bank, Korle-bu Teaching Hospital were 
recruited for the study. Blood samples were screened 
for Sickle cell haemoglobin and those with sickle cell 
trait (HbAS as well as HbAC) were excluded. Five ml 
of venous blood was collected from the subjects into 
EDTA tubes for sickling test, Haemoglobin Electro-
phoresis, HbF and haemoglobin concentration determi-
nations.  
 
Sickling test for controls (screening) was by sodium 
metabisulfitemethod.40 Measurement of HbF levels 
were by alkaline denaturation method as described by 
Singer and others.41 VOC was clinically defined as 
pains in the bones, muscles and joints not attributable 
to any other cause and requiring parenteral analgesia 
and admitted in the Centre for more than an hour. The 
Frequencies of VOC was rerecorded by the number of 
times patients were hospitalized during the period of 
the study by a questionnaire.  
 
All subjects gave their informed consent. Ethical clear-
ance for this study was given by the Ethical and proto-













Paired and unpaired student t-test was used to compare 
differences between and within sex-matched means in 
the groups, but these were not statistically significant. 
However, analysis of variance (ANOVA) gave signifi-
cant results in Hb and HbF levels (Table 1). 
 
Table 1 Haemorheological parameters in the studied 
groups 
 
*Mean standard deviation; Sickle cell patients appear 
younger than controls but this was not statistically sig-
nificant after analysis of variance was done; p-values 
less than 0.05 were said to be significant. 
 
 
Figure 1 Hb F levels and frequency of vaso=occlusive 
crises in sickle cell Hb SS disease patients.  
 
HbF effects on the clinical manifestations on SCD 
were slightly variable (Figures1 and 2).This conforms 
to previous studies that stated `threshold levels' above 
which HbF could be an ameliorating factor.21, 29-31 
 
 
The higher the HbF level in an individual, the lower the 




Figure 2 Hb F levels and frequency of vaso=occlusive 
crises in sickle cell Hb SC disease patients.  
 
HbF appears to benefit some complications of disease 
more than others (Figures 1 and 2). This might be re-
lated to the premature destruction of erythrocytes that 
do not contain HbF, even though the total HbF concen-
tration was high. 
 
DISCUSSION 
In this study, HbF levels were significantly higher in 
SCD patients than in controls. This was consistent with 
the finding of Konotey-Ahulu.1 The high levels of HbF 
in SCD patients may suggest that increased foetal hae-
moglobin concentrations may have beneficial effects in 
SCD22,24This is because increased cellular levels of 
HbF reduces the tendency of deoxygenated HbS to 
polymerize since HbF interferes with the intracellular 
polymerization of HbS42.Therefore, HbF confers a sur-
vival advantage to erythrocytes in proportion to the 
amount of HbF present43 and has beneficial effects on 
patients with SCD. 
 
HbF effects on the clinical manifestations on SCD 
were slightly variable. This conformed to previous 
studies that stated `threshold levels' above which HbF 
could be an ameliorating factor.21, 25-26, 29-31The particu-
lar threshold is still a subject of concern.  
 
Furthermore, haplotypes of the β-globin gene cluster 
and α-globin complement affecting the expression of 
factors such as HbF, also modulate SCD severity. Hap-
lotypes of the HbS allele have been identified from 
various populations of distinct polymorphic clusters.  
Males SC20 SS16 AA83 
p-values 
Age 29.6±13.1* 25.3±11.5 30.0±7.0 
0.159 
Hb 11.1±3.8 7.9±2.6 14.0±1.7 
0.000 
HbF 8.2±2.8 8.4±2.9 1.1±0.5 
0.000 
Females SC26 SS18 AA19 
 
Age 23.1±10.9 25.1±11.4 28.8±7.2 
0.187 
Hb 11.2±2.3 8.0±2.8 14.1±2.1 
0.000 








These clusters are thought to correlate with hematolog-
ical markers and HbF gene expression which impact on 
disease severity. To shed more light on these, more 
sensitive studies like high performance liquid chroma-
tography for HbF determination and targeted genomic 
analysis are needed. 
 
A limitation of our study was the small sample size that 
was comparable to literature cited. Nonetheless, these 
findings add to the small body of literature concerning 
SCD severity.  
 
CONCLUSION 
Threshold values of HbF play a role in reducing the 
frequency of vaso-occlusive crisis in SCD patients and 
this finding contributes to the body of available litera-
ture on SCD severity. However our work does not give 
the apparent threshold level of helpful HbF Level in 
SCD.   
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